Skip to main content
Fig. 4 | Pilot and Feasibility Studies

Fig. 4

From: Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19

Fig. 4

Biochemical parameters. The serumic level of BUN in control (A) and intervention (B) groups' patients. Creatinine (Cr) measurement in serum of control (C), and intervention groups (D). ALT serumic level in all patients of the control (E) and intervention (F) groups. AST serumic level measurement in control (G) and intervention (H) groups. ALP serumic level evaluation in patients of the control (I) and the intervention (J) groups. The quantitative CRP in control (K) and intervention (L) groups. The serum level of IL-6 in control (M) and intervention (N) groups. The LDH in control (O) and intervention (P) groups’ patients

Back to article page

Pilot and Feasibility Studies

ISSN: 2055-5784